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Abstract
Background Bevacizumab is frequently combined with
5-Xuorouracil-based chemotherapy for patients with meta-
static colorectal cancer (mCRC). The relative beneWt of
bevacizumab in older patients has not been widely studied
and is of interest.
Patients and methods This retrospective analysis used
data from three Wrst-line randomized controlled studies and
one second-line randomized controlled study of bev-
acizumab plus chemotherapy in medically Wt (Eastern
Cooperative Oncology Group performance status 0 or 1)
patients with mCRC. Overall survival (OS) and on-treat-
ment progression-free survival (PFS) were assessed in
patients aged <65, ¸65, and ¸70 years. Results were com-
pared using unstratiWed hazard ratios (HRs). Grade 3–5
adverse events were also assessed.
Results Bevacizumab statistically signiWcantly improved
PFS [HR 0.58; 95% conWdence interval (CI) 0.49–0.68]
and OS (HR 0.85; 95% CI 0.74–0.97) in patients aged
¸65 years; patients aged ¸70 years had similar improve-
ments. BeneWts were consistent across the studies, irrespec-
tive of setting, bevacizumab dose, or chemotherapy
regimen. Increases in thromboembolic events were
observed in patients aged ¸65 and ¸70 years in the bev-
acizumab group compared with the control group, mainly
as a result of increases in arterial thromboembolic events.
No other substantial age-related increases in grade 3–5
adverse events were observed.
Conclusions In medically Wt older patients, bevacizumab
provides similar PFS and OS beneWts as in younger
patients.
Keywords Bevacizumab · Chemotherapy · Metastatic 
colorectal cancer · Older patients · Pooled analysis
Introduction
Two-thirds of patients newly diagnosed with metastatic
colorectal cancer (mCRC) are aged ¸65 years and 40% of
cases occur in patients aged ¸75 years (Edwards et al.
2002). Older patients represent a heterogeneous population,
and chemotherapy in these individuals must be considered
alongside declining end organ function and physical and
psychological conditions that can compromise the eVective
administration of chemotherapy. Many clinical trials there-
fore exclude older patients, particularly those with poor
performance status, and few age-speciWc studies have been
published. Even in trials with no upper age limit, the pro-
portion of older and very old patients is usually small, prob-
ably reXecting the more conservative approach adopted by
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clinicians when treating these patients. Consequently,
fewer older patients are eligible for clinical trials and reli-
able evidence supporting the beneWts of chemotherapy in
this population is limited.
To overcome the underrepresentation of older patients
in clinical trials, pooled analyses have been performed to
investigate the eYcacy and tolerability of treatment in
more meaningful numbers of patients. Previous analyses
have indicated that chemotherapy with 5-Xuorouracil (5-
FU), 5-FU/oxaliplatin, or 5-FU/irinotecan is feasible for
selected older patients with mCRC (Folprecht et al. 2004,
2008; Goldberg et al. 2006). Folprecht and colleagues
(2008) reported that patients aged ¸70 years did not
generally experience greater toxicity than younger patients,
although hepatotoxicity was more common in older
patients. These analyses provide a strong rationale for the
treatment of suitable older patients with eVective chemo-
therapy.
Bevacizumab is commonly used with chemotherapy in
the treatment of patients with mCRC. Most patients
included in bevacizumab clinical trials have been <65 years
old, and thus its eYcacy and tolerability in older patients
are less well established. A previous pooled analysis exam-
ined the eYcacy and safety of bevacizumab in 438 patients
(Kabbinavar et al. 2009). Since that analysis was under-
taken, the results of larger, randomized, placebo-controlled
studies have become available, thus expanding the number
of older patients for whom eYcacy and safety data are
available. The present retrospective analysis was therefore
undertaken to compare the eYcacy and safety of bev-
acizumab plus chemotherapy in older versus younger
patients with mCRC who participated in four randomized
phase II and III trials that included over 1,100 patients aged
¸65 years.
Patients and methods
Study design
This analysis included data from three Wrst-line
[AVF2107g (Hurwitz et al. 2004); AVF2192g (Kabbinavar
et al. 2005); NO16966 (Saltz et al. 2008)] and one second-
line [E3200 (Giantonio et al. 2007)] multicenter randomized
trials. Patients were treated with Xuoropyrimidine-based
chemotherapy with or without bevacizumab. Only the
principal arms in these studies were included in the current
analysis. In study NO16966, patients were treated with
Wrst-line oxaliplatin + 5-FU/leucovorin (LV) (FOLFOX4)
or capecitabine (XELOX) § bevacizumab (Saltz et al.
2008). Patients in AVF2107g were initially randomized to
5-FU/LV + bevacizumab, 5-FU/LV + irinotecan (IFL) +
placebo, or IFL + bevacizumab, although recruitment to the
5-FU/LV plus bevacizumab arm was halted after an interim
analysis (Hurwitz et al. 2004). Patients in AVF2192g were
randomized to 5-FU/LV + placebo or bevacizumab (Kabbi-
navar et al. 2005) and patients in study E3200, who had
failed previous Xuoropyrimidine–irinotecan therapy, were
randomized to FOLFOX4 § bevacizumab (Giantonio et al.
2007).
Assessments
Overall survival (OS) and on-treatment progression-free
survival (PFS)—common endpoints in all four trials—
were evaluated in patients <65 years, ¸65 years, and
¸70 years in each study and as a pooled analysis. Inten-
tion to treat PFS was not evaluated in all of the four stud-
ies. On-treatment PFS was a secondary endpoint in all
four trials; OS was the primary endpoint in AVF2107g,
AVF2192g, and E3200 and a secondary endpoint in
NO16966.
DeWnitions of on-treatment PFS varied by study. In
NO16966, patients were censored for curative surgery but
not for other second-line treatment. On-treatment analysis
included tumor assessments and death occurring
·28 days after the last study medication intake during the
primary treatment phase. Patients without an event during
this phase were censored at the last tumor assessment date
or on day 1 if no post-baseline assessment was available.
Patients with curative-intent surgical resection without
prior progression ·28 days after the last study medication
intake in the primary phase were censored at the surgery
date. In AVF2107g and AVF2192g, on-treatment PFS
was deWned as the time from randomization to disease
progression or death from any cause during Wrst-line ther-
apy (deaths ·30 days after the last study drug dose during
Wrst-line treatment were considered as events). In E3200,
clinical deterioration was not considered an event; censor-
ing was performed for second-line treatment. PFS was
deWned as the time from randomization to disease pro-
gression or any-cause death ·30 days after study treat-
ment discontinuation. Data for patients without disease
progression or death at the time of analysis were censored
at the last tumor assessment ·30 days after the last dose
(or, if no post-baseline tumor assessments were per-
formed, at the time of randomization plus 1 day). Data for
patients who discontinued any treatment component or
received nonprotocol-speciWed therapy before disease
progression were censored at the time of the last tumor
assessment during treatment.
Adverse events of interest for bevacizumab were
assessed by age group. Data collection varied among trials;
only grade 3–5 data were collected consistently in the
studies and only these events were pooled for the current
analysis.J Cancer Res Clin Oncol (2010) 136:737–743 739
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Statistical analyses
EYcacy analysis was based on all randomized patients
(intent-to-treat analysis). The primary outcome was OS,
deWned as time from randomization to death. PFS, deWned
as time from randomization to disease progression or death
from any cause during Wrst-line treatment, was a secondary
outcome.
Integrated analyses were stratiWed by study. Unstrati-
Wed hazard ratios (HRs) and 95% conWdence intervals
(CIs) were calculated for each study to allow compari-
sons. Results therefore diVer slightly from the primary
analyses of each study report: for example, the primary
analysis of NO16966 used a 97.5% CI and was stratiWed
by chemotherapy treatment (Saltz et al. 2008). The
unstratiWed point estimate (HR) for NO16966, however,
remains the same as that in the study report. Similarly, for
the other three studies, the results shown are for the
unstratiWed analysis, i.e. not stratifying according to the
stratiWcation variables used at randomization. Kaplan–
Meier methods were used to estimate median OS and
on-treatment PFS durations. Durations of OS and on-
treatment PFS in the pooled bevacizumab group and the
pooled control group were compared using two-sided
stratiWed log-rank tests.
Results
In total, 3,007 patients were eligible for inclusion in the
analysis; 1,864 were aged <65 years (914, 542, 41, and 367
patients in studies NO16966, AVF2107g, AVF2192g, and
E3200, respectively), 1,142 were ¸65 years (486, 271, 168,
and 217 patients, respectively), 712 patients were
¸70 years (268, 176, 138, and 130 patients, respectively),
and the age of one patient was unknown. Patient baseline
characteristics were generally well balanced between the
age groups (Table 1). A general worsening of Eastern
Cooperative Oncology Group performance status (ECOG
PS) was observed with age.
EYcacy of bevacizumab by age group
Addition of bevacizumab to chemotherapy signiWcantly
prolonged PFS in older and younger patients (Fig. 1a–c).
The magnitude of PFS beneWt was similar in both older
(aged ¸65 years and ¸70 years) and younger patients. In
patients aged <65 years, median PFS was 9.5 months for
bevacizumab versus 6.7 months for the control
(P < 0.0001); in those aged ¸65 years, median PFS was
9.3 months for bevacizumab versus 6.9 months for the con-
trol (P < 0.0001); and in those aged ¸70 years, median PFS
was 9.2 months for bevacizumab versus 6.4 months for the
control (P < 0.0001). HRs are shown in Table 2. Point esti-
mates were consistent across the trials, indicating a similar
treatment eVect irrespective of setting (Wrst or second line),
bevacizumab dose (2.5 mg/kg/week or 5 mg/kg/week),
chemotherapy regimen (5-FU/LV, IFL, XELOX, or FOL-
FOX4), or age.
Adding bevacizumab to chemotherapy statistically sig-
niWcantly prolonged OS in both older and younger patients
(Table 2; Fig. 1d–f), although the magnitude of eVect was
smaller than for PFS. When OS data from the individual
studies were analyzed by age, results for the age groups
were generally similar to the overall study data. In patients
aged <65 years, median OS was 19.9 months for bev-
acizumab versus 16.5 months for the control (P < 0.0001);
in those aged ¸65 years, median OS was 17.9 months for
bevacizumab versus 15.0 months for the control
(P = 0.015); and in those aged ¸70 years, median OS was
17.4 months for bevacizumab versus 14.1 months for the
control (P =0 . 0 0 5 ) .
Table 1 Patient characteristics at baseline (n =3 , 0 0 7 )
bev bevacizumab, ECOG PS Eastern Cooperative Oncology Group performance status
Characteristic <65 years ¸65 years ¸70 years All
Bev 
(n = 930)
Control 
(n = 934)
Bev 
(n = 567)
Control 
(n = 575)
Bev 
(n =3 6 2 )
Control 
(n =3 5 0 )
Bev 
(n =1 , 4 9 8 )
Control 
(n = 1,509)
Median age, 
years (range)
56 (18–64) 54 (18–64) 72 (65–89) 71 (65–90) 74 (70–89) 74 (70–90) 61 (18–89) 61 (18–90)
Sex, n (%)
Male 540 (58) 526 (56) 350 (62) 344 (60) 227 (63) 200 (57) 890 (59) 870 (58)
Female 390 (42) 408 (44) 217 (38) 231 (40) 135 (37) 150 (43) 608 (41) 639 (42)
ECOG PS, n (%)
0 533 (58) 536 (57) 276 (49) 286 (50) 163 (45) 161 (46) 809 (54) 822 (55)
1 381 (41) 382 (41) 278 (49) 277 (48) 190 (52) 179 (51) 660 (44) 659 (44)
2 12 (1) 15 (2) 12 (2) 10 (2) 9 (2) 8 (2) 24 (2) 25 (2)740 J Cancer Res Clin Oncol (2010) 136:737–743
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Safety of bevacizumab by age group
Rates of adverse events of special interest with bev-
acizumab are shown in Fig. 2. Bleeding, hypertension, pro-
teinuria, arterial thromboembolic events (ATEs), venous
thromboembolic events (VTEs), wound-healing complica-
tions, Wstulae, gastrointestinal perforation, and congestive
heart failure were more common in bevacizumab-treated
patients. ATEs and VTEs were more frequent in older ver-
sus younger patients in the control and bevacizumab
groups. In patients aged <65 years, there was no diVerence
in ATE rates in the bevacizumab and control groups (2%
incidence in both groups). However, in patients aged
¸65 years, the ATE rate was 5.7% for bevacizumab
patients versus 2.5% for the control group; in patients aged
¸70 years, the incidence of ATEs was 6.7% with bev-
acizumab versus 3.2% with control. In contrast, VTEs were
consistently 1–2% more frequent with bevacizumab versus
control, but did not appear to increase to a relatively greater
degree with age. Gastrointestinal perforations occurred in
14 bevacizumab-treated patients (<1%; eight events in
patients <65 years and six in patients ¸65 years, four of
which occurred in patients aged ¸70 years) and two control
patients (<1%; both aged <65 years).
Adverse events leading to death occurred in 17 bev-
acizumab-treated patients; seven were aged <65 years and
10 were aged ¸65 years. Eleven control group patients had
adverse events leading to death; Wve were aged <65 years
and six were aged ¸65 years. In patients aged ¸70 years,
adverse events resulting in death occurred in six bev-
acizumab-treated patients and three control group patients.
Rates of on-study death from any cause appeared to be
lower in bevacizumab-treated patients (<65 years 69 vs.
75%, ¸65 years 74 vs. 77%, ¸70 years 76 vs. 81%, for
Fig. 1 Progression-free sur-
vival and overall survival strati-
Wed by age across randomized 
trials in patients with metastatic 
colorectal cancer. Progression-
free survival in patients aged 
a <65 years, b ¸65 years, and 
c ¸70 years; overall survival in 
patients aged d <65 years, 
e ¸65 years, and f ¸70 years
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bevacizumab vs. control, respectively). The proportion of
nontumor-related deaths increased with age, from 18% in
patients aged <65 years (17% for bevacizumab vs. 19% for
control) to 22% in those aged ¸65 years (23% for bev-
acizumab vs. 21% for control) and 25% in those aged
¸70 years (25% for bevacizumab vs. 22% for control).
Discussion
The most signiWcant Wnding of this retrospective explor-
atory pooled analysis of trials comparing chemotherapy
plus bevacizumab with chemotherapy alone in mCRC was
that within this protocol-eligible population, older and
younger patients appeared to achieve similar survival
beneWts from bevacizumab treatment. Improvements in
PFS were comparable in patients aged <65 years, ¸65
years, and ¸70 years, with HRs of 0.59, 0.58, and 0.54,
respectively. Patients also showed statistically signiWcant
prolongation of median PFS with the addition of bev-
acizumab to their treatment, with a similar magnitude of
PFS improvement in younger and older patients. The eVect
of bevacizumab was consistent across age groups in each
study. Although statistically signiWcant, the eVect of bev-
acizumab on OS in older patients was not so pronounced as
its eVect on PFS, reXected by HRs of 0.77, 0.85, and 0.79
for patients aged <65 years, ¸65 years, and ¸70 years,
respectively. Several reasons are possible: older bev-
acizumab patients were more likely to be less Wt, with 41%
of patients aged <65 years, 49% aged ¸65 years, and 52%
Table 2 Hazard ratios for on-treatment progression-free survival and overall survival by age across randomized trials in patients with metastatic
colorectal cancer who were treated with chemotherapy with or without bevacizumab
CI conWdence interval
a One patient had no recorded age, therefore the age subgroups contain 3,006 patients in total
Study Hazard ratio according to age (95% CI)
<65 years (n = 1,864) ¸65 years (n = 1,142) ¸70 years (n = 712) All (n =3 , 0 0 7 ) a
Progression-free survival
Pooled analysis 0.59 (0.52–0.66) 0.58 (0.49–0.68) 0.54 (0.44–0.66) 0.58 (0.53–0.64)
NO16966 0.62 (0.51–0.76) 0.65 (0.50–0.86) 0.60 (0.41–0.88) 0.63 (0.54–0.74)
AVF2107g 0.58 (0.47–0.71) 0.57 (0.42–0.77) 0.52 (0.35–0.76) 0.58 (0.49–0.68)
AVF2192g 0.56 (0.27–1.18) 0.51 (0.36–0.74) 0.49 (0.33–0.74) 0.55 (0.40–0.76)
E3200 0.53 (0.41–0.70) 0.53 (0.37–0.76) 0.53 (0.33–0.84) 0.53 (0.43–0.66)
First-line studies 0.60 (0.52–0.69) 0.59 (0.49–0.71) 0.54 (0.43–0.67) 0.60 (0.54–0.67)
Overall survival
Pooled analysis 0.77 (0.69–0.86) 0.85 (0.74–0.97) 0.79 (0.66–0.93) 0.80 (0.74–0.87)
NO16966 0.81 (0.69–0.96) 1.05 (0.84–1.31) 0.99 (0.74–1.33) 0.89 (0.78–1.02)
AVF2107g 0.77 (0.63–0.94) 0.63 (0.48–0.84) 0.64 (0.46–0.91) 0.73 (0.62–0.85)
AVF2192g 0.51 (0.22–1.15) 0.83 (0.59–1.16) 0.76 (0.52–1.09) 0.80 (0.59–1.09)
E3200 0.72 (0.58–0.90) 0.80 (0.60–1.06) 0.73 (0.51–1.04) 0.75 (0.63–0.89)
First-line studies 0.79 (0.69–0.89) 0.86 (0.74–1.00) 0.80 (0.67–0.97) 0.82 (0.74–0.90)
Fig. 2 Adverse events of inter-
est for bevacizumab in random-
ized trials of patients with 
metastatic colorectal cancer. 
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aged ¸70 years being ECOG PS 1. Also, older patients had
more comorbidities, as indicated by a higher rate of non-
cancer-related deaths in both arms.
The risk–beneWt proWle of bevacizumab treatment in
these medically Wt, older patients did not substantially alter
with age for most toxicities recorded. Hypertension, bleed-
ing, and proteinuria were the most commonly reported side
eVects, as previously described (Hurwitz and Saini 2006).
Toxicity rates were generally similar in older and younger
patients, although thromboembolic events, which increase
in frequency with advancing age (Silverstein et al. 1998;
Abbott et al. 2003; Goldberg et al. 1989), were more com-
mon in older patients in both the bevacizumab and control
groups. The present study corroborates earlier reports that
the risk of bevacizumab-related ATEs increases with age
(Scappaticci et al. 2007). There were more ATEs in older
bevacizumab-treated patients compared with younger bev-
acizumab-treated patients and, while the incidence of ATEs
in patients aged <65 years was essentially similar with or
without bevacizumab, the incidence was higher in bev-
acizumab versus control patients aged ¸65 and ¸70 years.
There was no apparent increase in VTE rates with advanc-
ing age, consistent with previous reports. Among older
patients in the BRiTE registry, the incidence of thrombo-
embolic events increased with age, although the increase
was not statistically signiWcant after adjustment for baseline
ECOG PS and prior history of thromboembolic events
(KozloV et al. 2008). The incidence of other bevacizumab-
related events was similar in younger and older patients in
BRiTE.
The present analysis complements and expands upon the
Wndings of the smaller pooled analysis of older patients by
Kabbinavar and colleagues (2009), which reported a beneWt
of adding bevacizumab to chemotherapy in medically Wt
patients aged ¸65 years without an increased risk
of adverse events. As well as including a larger number of
patients, the present analysis has the added advantage
of directly comparing older and younger patients in contrast to
the earlier study, in which the group of older patients was
compared with the total population, rather than the younger
patients. Taken together, these analyses suggest that bev-
acizumab-treated older patients who meet eligibility
requirements for clinical trials are not at increased risk of
adverse events, other than ATEs, compared with those aged
<65 years. The present analysis of older patients considered
those aged ¸65 years, higher than the median age in the
pooled population, and supplemented this with an analysis
of those aged ¸70 years, which more closely reXects the
general population of patients presenting with colorectal
cancer. It should be emphasized that patients in the present
analysis and in the other studies cited were clinical-trial
eligible and may not be representative of a more general
elderly population. Careful selection of patients and
monitoring of treatment eVects are required to optimize
bevacizumab use in older patients.
In conclusion, this pooled analysis of data from phase II
and III mCRC studies demonstrates that bevacizumab in
combination with chemotherapy had a similar impact on
PFS and OS in protocol-eligible older versus younger
patients. Careful patient selection, however, remains impor-
tant and should include an objective assessment of the
patient’s physical and mental status.
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